Randomised Phase II Trial to Evaluate the Strategy of Integrating Local Ablative Therapy with First-Line Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer
This study aims to assess the clinical benefit of local ablative therapy (LAT) following initial standard fist-line systemic treatment, compared to continued standard first-line systemic treatment in patients with unresectable oligometastatic CRC.
Primary Sponsor
AGITG
Collaborating Groups
TROG Cancer Research
Participating Centres
Accrual Target
74
Current Accrual
Trial Chairperson
Dr Julie Chu
Trial Contact
qa@trog.com.au
Related Post
February 28, 2022
Cancer trial participant hoping to help
The RAVES trial treating prostate cancer Participating in a
June 15, 2021
Individualising radiotherapy for women with DCIS of the breast reduces recurrence after surgery
Ductal carcinoma in situ (DCIS) of the breast is
